Correction to Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg)

IF 4.3 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Helicobacter Pub Date : 2024-08-07 DOI:10.1111/hel.13124

引用次数: 0

Abstract

S. J. Martínez-Domínguez, O. P. Nyssen, A. Lanas, et al., “Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg),” Helicobacter 29, no. 4 (2024): e13111.

The corresponding author email was incorrect. The correct corresponding author email is [email protected].

We apologize for this error.

查看原文本刊更多论文

幽门螺杆菌根除治疗适应症的更正及其对处方和疗效的影响（Hp-EuReg）。

S.J. Martínez-Domínguez, O. P. Nyssen, A. Lanas, et al., "Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg)," Helicobacter 29, no.4 (2024): e13111.通讯作者的电子邮件有误。正确的通讯作者邮箱是 [email protected]。我们对此错误深表歉意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Helicobacter 医学-微生物学

CiteScore

8.40

自引率

9.10%

发文量

审稿时长

2 months

期刊介绍： Helicobacter is edited by Professor David Y Graham. The editorial and peer review process is an independent process. Whenever there is a conflict of interest, the editor and editorial board will declare their interests and affiliations. Helicobacter recognises the critical role that has been established for Helicobacter pylori in peptic ulcer, gastric adenocarcinoma, and primary gastric lymphoma. As new helicobacter species are now regularly being discovered, Helicobacter covers the entire range of helicobacter research, increasing communication among the fields of gastroenterology; microbiology; vaccine development; laboratory animal science.